Each week we highlight five things affecting the life sciences industry. Here's the latest. FTC appointments possibly signal decreased scrutiny on biopharma M&A President-elect Donald Trump's nomination of Andrew Ferguson and Mark Meador to the Federal Trade Commission signals a potential shift ... READ MORE >
FTC
5 things to know in life sciences: Week of May 15, 2023
This week we look at how changes to accelerated approvals at the U.S. Food and Drug Administration (FDA) are affecting the number of drugs being approved. Also this week, there is news of CVS’s brief foray into clinical trials, the end of the public health emergency for COVID-19, and the costs of the ... READ MORE >
Drug pricing and health care innovation could benefit from Biden’s latest executive order
On July 9, President Biden issued an executive order on promoting competition in the American economy that could have significant ramifications for health care systems. The order indicates that the pace of business consolidation has accelerated and that “in over 75% of U.S. industries, a smaller number ... READ MORE >
5 things to know in life sciences: Week of June 14
Given the high volume of mergers and acquisitions in life sciences, changes in the leadership and focus of the Federal Trade Commission will be closely watched in the coming months as scrutiny could shift to the technology industry. We examine the possible impact below. We also look at CureVac’s ... READ MORE >